| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H16N2O2 |
| Molecular Weight | 304.3425 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OCC1=CC=C(O1)C2=NN(CC3=CC=CC=C3)C4=C2C=CC=C4
InChI
InChIKey=OQQVFCKUDYMWGV-UHFFFAOYSA-N
InChI=1S/C19H16N2O2/c22-13-15-10-11-18(23-15)19-16-8-4-5-9-17(16)21(20-19)12-14-6-2-1-3-7-14/h1-11,22H,12-13H2
Lificiguat (YC-1) [3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole], a chemically synthetic benzylindazole compound, is a direct soluble guanylate cyclase activator. It possessed antiplatelet activity. YC-1 inhibits Hypoxia-inducible factor-1 (HIF-1). YC-1 demonstrated antineoplastic potential both in vitro and in vivo in animal models.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Lificiguat (YC-1) was tested on in vivo model of pulmonary arterial hypertension. To assess preventive or therapeutic effects, randomized mice were subjected to once daily i.p. injections of YC-1 for the entire hypoxic period (5 mg/kg) or for the last seven days of a 28-day hypoxic period (5 and 10 mg/kg).
Route of Administration:
Intraperitoneal
ACTIVE MOIETY
